Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDUA | P35475 | 1/20 | 0.47 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FGF2 | P09038 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 2/20 | 0.32 |
| ▸ | SELL | P14151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13969565 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL13377847 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL8340283 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL19848245 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL13478556 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL15473351 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL23502390 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL13887430 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL17906334 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 | |
| SCHEMBL749480 | 1.00 | IDUA (0.47) | IDUASUCNR1CA9CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | SYMBERIX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2023146892-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20220411423-A1 | DERIVATIVES OF AN FGFR INHIBITOR | INCYTE CORPORATION | 2022-12-29 | — | — | US | disclosed |
| US-20210171522-A1 | DERIVATIVES OF AN FGFR INHIBITOR | INCYTE CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. | 2021-04-01 | — | — | US | disclosed |
| WO-2019051185-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING β-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | SYMBERIX, INC. (US) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171522-A1 | DERIVATIVES OF AN FGFR INHIBITOR | FGFR1, FGFR2, FGFR4 | IDUA 1232/4885SUCNR1 307/4885CA9 1068/4885 |
| US-12017994-B2 | Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrhea | GUSB, SI, ENGASE | IDUA 89/4885SUCNR1 924/4885CA9 569/4885 |
| US-20210094917-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING B-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | GUSB, SI, UGT2B7 | IDUA 84/4885SUCNR1 1199/4885CA9 663/4885 |
| US-20220411423-A1 | DERIVATIVES OF AN FGFR INHIBITOR | FGFR1, FGFR2, FGFR4 | IDUA 1232/4885SUCNR1 307/4885CA9 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.